January 2015: the Medicines and Healthcare Products Regulatory Agency (MHRA) has strengthened its warnings on the use of valproate in women of childbearing potential. NICE is currently assessing the impact of this on its bipolar disorder guideline (CG185). In the meantime, healthcare professionals are advised to use the guideline in conjunction with the latest MHRA advice.
This guideline updates and replaces NICE clinical guideline 38 (published July 2006). It offers evidence based advice on the care and treatment of children, young people and adults with bipolar disorder.
All areas of NICE clinical guideline 38 have been updated.